2025 – Page 2 – Talk Bio

Actionable Insights Powered by AI

Thermo Fisher Forecasts Revenue Growth in 2025 Amid Easing Market Challenges

6 months ago talkbio0Tagged 2025, Analytical Instruments, Growth, headwinds, Laboratory Products, pharmaceutical sector, Thermo Fisher Scientific

Thermo Fisher Scientific, revenue forecast, 2025 growth, easing headwinds, biotech funding, pharmaceutical sector, laboratory products, analytical instruments.

Bayer Acquires European Rights to BridgeBio’s Acoramidis for ATTR-CM Therapy

1 year ago talkbio0Tagged 2025, Acoramidis, Approved, ATTR-CM, Bayer, Blockbuster Potential, BridgeBio Pharma, Cardiovascular Infrastructure, Clarity, Clinical action, EMA Approval, European Rights, Exclusive License, Hope (emotion), investor, low-thirties, milestone payments, November 2024, PDUFA, Phase 3 Data, royalties, Split Strategy, Vyndaqel Rival

Bayer, BridgeBio Pharma, Acoramidis, ATTR-CM, Exclusive License, European Rights, Royalties, Milestone Payments, Phase 3 Data, Potential Approval, Low-Thirties Percent Royalties, EMA Approval 2025, PDUFA Action Date November 2024, Vyndaqel Rival, Blockbuster Potential, Cardiovascular Infrastructure, Investor Hopes for Clarity on Split Strategy.